Literature DB >> 27825722

Current status of HIV/AIDS in the ART era.

Kazuhisa Yoshimura1.   

Abstract

Human immunodeficiency virus (HIV) spread to humans from chimpanzees (HIV-1 groups M and N), gorillas (HIV-1 groups P and O), and sooty mangabeys (HIV-2). HIV is spread mainly through blood or body fluids. Subjects can become infected with HIV by sexual contact, needle sharing, blood transfusions, or maternal transmissions as a blood-borne virus or via breast-milk. The incubation period of HIV-1 from infection to the development of AIDS ranges from 8 to 11 years. In the past 3 decades, HIV has caused a great burden to global wealth and health. According to the WHO global health survey, 36.7 million people were infected with HIV, causing 1.1 million deaths in 2015. Since the discovery of HIV-1, many anti-retroviral drugs have been developed. Following the discovery and wide-spread use of anti-retroviral therapy (ART) the life expectancy of HIV infected individuals has substantially increased. By 2015, all major guidelines recommended treating all HIV-infected adults regardless of their CD4 count. Despite effective ART with virological suppression, HIV-associated neurocognitive disorders (HAND), cardiovascular diseases (CVD), metabolic syndrome (MS), bone abnormalities and non-HIV-associated malignancies remain a major complication associated with HIV infection. In this review article, I would like to describe recent ART status and problems in the ART-era.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Anti-retroviral therapy (ART); HIV-associated neurocognitive disorders (HAND); Human immunodeficiency virus (HIV); Non-HIV-associated malignancies

Mesh:

Substances:

Year:  2016        PMID: 27825722     DOI: 10.1016/j.jiac.2016.10.002

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  30 in total

1.  The unmet clinical need of novel antifungal drugs.

Authors:  Damian J Krysan
Journal:  Virulence       Date:  2017-02-17       Impact factor: 5.882

2.  Refining Current Scientific Priorities and Identifying New Scientific Gaps in HIV-Related Heart, Lung, Blood, and Sleep Research.

Authors:  Homer L Twigg; Ronald Crystal; Judith Currier; Paul Ridker; Nancy Berliner; Hans-Peter Kiem; George Rutherford; Shimian Zou; Simone Glynn; Renee Wong; Emmanuel Peprah; Michael Engelgau; Tony Creazzo; Sandra Colombini-Hatch; Elisabet Caler
Journal:  AIDS Res Hum Retroviruses       Date:  2017-06-26       Impact factor: 2.205

Review 3.  Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors.

Authors:  Maxime J Jean; Guillaume Fiches; Tsuyoshi Hayashi; Jian Zhu
Journal:  AIDS Res Hum Retroviruses       Date:  2018-12-12       Impact factor: 2.205

4.  Structure-optimized dihydropyranoindole derivative GIBH-LRA002 potentially reactivated viral latency in primary CD4+ T lymphocytes of chronic HIV-1 patients.

Authors:  Qing Yang; Yuyang Ding; Fengling Feng; Enxiang Pan; Xiaozhen Fan; Xiuchang Ma; Ling Chen; Junling Zhao; Caijun Sun
Journal:  Medchemcomm       Date:  2017-07-25       Impact factor: 3.597

5.  P2X1 Selective Antagonists Block HIV-1 Infection through Inhibition of Envelope Conformation-Dependent Fusion.

Authors:  Alexandra Y Soare; Hagerah S Malik; Natasha D Durham; Tracey L Freeman; Raymond Alvarez; Foramben Patel; Namita Satija; Chitra Upadhyay; Catarina E Hioe; Benjamin K Chen; Talia H Swartz
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

6.  HIV transmission in discordant couples in Africa in the context of antiretroviral therapy availability.

Authors:  Evonne Woodson; Alec Goldberg; Clive Michelo; Debby Basu; Sijia Tao; Raymond Schinazi; Yong Jiang; William Kilembe; Etienne Karita; Susan Allen; Eric Hunter
Journal:  AIDS       Date:  2018-07-31       Impact factor: 4.177

7.  Blood-based inflammation biomarkers of neurocognitive impairment in people living with HIV.

Authors:  Naomi Swanta; Subhash Aryal; Vicki Nejtek; Sangeeta Shenoy; Anuja Ghorpade; Kathleen Borgmann
Journal:  J Neurovirol       Date:  2020-03-19       Impact factor: 2.643

8.  P2X Antagonists Inhibit HIV-1 Productive Infection and Inflammatory Cytokines Interleukin-10 (IL-10) and IL-1β in a Human Tonsil Explant Model.

Authors:  Alexandra Y Soare; Natasha D Durham; Ramya Gopal; Benjamin Tweel; Kevin W Hoffman; Julia A Brown; Megan O'Brien; Nina Bhardwaj; Jean K Lim; Benjamin K Chen; Talia H Swartz
Journal:  J Virol       Date:  2018-12-10       Impact factor: 5.103

9.  Inhibition of the Dead Box RNA Helicase 3 Prevents HIV-1 Tat and Cocaine-Induced Neurotoxicity by Targeting Microglia Activation.

Authors:  Marina Aksenova; Justin Sybrandt; Biyun Cui; Vitali Sikirzhytski; Hao Ji; Diana Odhiambo; Matthew D Lucius; Jill R Turner; Eugenia Broude; Edsel Peña; Sofia Lizarraga; Jun Zhu; Ilya Safro; Michael D Wyatt; Michael Shtutman
Journal:  J Neuroimmune Pharmacol       Date:  2019-12-04       Impact factor: 4.147

10.  Incorporation of docosahexaenoic acid (DHA) enhances nanodelivery of antiretroviral across the blood-brain barrier for treatment of HIV reservoir in brain.

Authors:  Pengbo Guo; Mengjie Si; Di Wu; Hui Yi Xue; Wenhui Hu; Ho Lun Wong
Journal:  J Control Release       Date:  2020-10-01       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.